Theragent

Executive Summary

Theragent is a privately held, full-service CDMO specializing in cell and gene therapy manufacturing, based in Arcadia, California. Founded in 2018, the company operates a cGMP-compliant facility offering integrated discovery platforms, state-of-the-art technologies, and regulatory expertise to support clients from preclinical development through commercial production. As the cell and gene therapy market expands, Theragent is positioned to capitalize on increasing demand for outsourced manufacturing, particularly among small-to-mid-sized biotechs lacking in-house capabilities. Although the company has not disclosed funding or valuation, its focus on the growing CDMO sector in Southern California—a biotech hub—suggests potential for steady growth. However, with no published pipelines or clinical-stage assets, the company's near-term commercial prospects are tied to client successes and capacity expansions.

Upcoming Catalysts (preview)

• Q3 2026Announcement of strategic partnership with a major cell therapy developer60% success
• Q4 2026Facility expansion or capacity addition to meet rising demand50% success
• TBDFDA approval of client therapy manufactured by Theragent, validating platform30% success